Skip to content Skip to footer
Subscribe Now
Genentech & Orionis
NEWS

Genentech Collaborates with Orionis to Identify and Develop Molecular Glue Therapies for Cancer Targets

Shots: Genentech has entered into a multi-year collaboration with Orionis to discover small-molecule monovalent glue drugs for novel & difficult oncology targets using Orionis’ Allo-Glue platform As per the deal, Orionis will receive $105M upfront & ~$2B in research, development, commercial, & sales milestones, with tiered royalties; Orionis will lead discovery & optimization, while Genentech…
May 22, 2025

Read more

Ramsoft & Therapixel
NEWS

RamSoft and Therapixel Form a Commercial Partnership For an Integrated AI Breast Imaging Solution

Shots: RamSoft Inc. and Therapixel have entered into a commercial partnership to integrate Therapixel’s MammoScreen AI-powered breast imaging software into RamSoft’s PowerServer and OmegaAI platforms This collaboration integrates Therapixel's MammoScreen, breast imaging AI, directly into RamSoft's platforms Recent studies showed that MammoScreen improves radiologist performance with 8% higher sensitivity, 2% higher specificity, and 24% faster…
May 21, 2025

Read more

Viz.ai, Sanofi & Regeneron
NEWS

Viz.ai Enters a Multi-Year Partnership with Sanofi and Regeneron to Improve Management and Care of COPD

Shots: Viz.ai has entered into a multi-year collaboration with Sanofi & Regeneron to deploy and evaluate its AI-powered chronic obstructive pulmonary disease (COPD) workflow solution Sanofi, Regeneron, and Viz.ai collaborated on an AI-powered solution to improve care for high-risk COPD pts, focusing on how the Viz COPD module can enhance EHR workflows, access to care,…
May 21, 2025

Read more

Vant AI & Blueprint Medicines
NEWS

VantAI and Blueprint Medicines Expands License Agreement to Advance Induced Proximity Drug Discovery

Shots: VantAI and Blueprint Medicines have expanded their 2022 collaboration, adding new drug target programs to develop therapies for critical medical needs As per the expansion, VantAI will receive up to $1.67B in total including ~$270M R&D and regulatory milestones, and $1.4B commercial milestones across four joint target programs, along with tiered mid-single-digit sales based…
May 21, 2025

Read more

Crispr Therapeutics & SIRIUS
NEWS

CRISPR Therapeutics Enters a Multi-Target Collaboration with Sirius Therapeutics to Develop Novel siRNA Therapies

Shots: CRISPR & Sirius have partnered to co-develop & co-market SRSD107, with CRISPR having the option to nominate ~2 siRNA targets, fund related research, & retain opt-in rights for clinical development & marketing As per the deal, Sirius will receive $25M cash & $70M in equity upfront, with both companies jointly developing SRSD107 under a…
May 20, 2025

Read more

23andMe
NEWS

Regeneron to Acquire 23andMe Assets for $256M

Shots: Regeneron has entered into an asset purchase agreement with 23andMe for $256M, strengthening Regeneron’s genetics-guided research & drug development activities Regeneron to acquire key assets of 23andMe, incl. Personal Genome Service, Total Health & Research Services business lines, plus its Biobank & associated assets, with services continuing uninterrupted; closing is expected in Q3’25 23andMe…
May 20, 2025

Read more

Skye Bioscience & Arecor Therapeutics
NEWS

Skye Bioscience Enters a Formulation Development Agreement with Arecor Therapeutics for Nimacimab

Shots: Skye Bioscience has partnered with Arecor Therapeutics to develop a higher concentration formulation of Skye’s nimacimab, leveraging Arecor’s Arestat formulation platform As per the deal, Skye will fund Arecor's development efforts, with the option to license rights of the new proprietary formulation & its intellectual property for further development & commercialization Nimacimab (CB1 inhibitor,…
May 19, 2025

Read more

Load more